Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
probiotics + norfloxacin
- Development stage
- Unknown
- Lead developer
- AIIMS New Delhi
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This therapeutic regimen consists of the multi-strain probiotic preparation VSL#3 and the fluoroquinolone antibiotic norfloxacin, evaluated by the All India Institute of Medical Sciences (AIIMS) for the prevention of spontaneous bacterial peritonitis (SBP) in patients with liver cirrhosis. Norfloxacin is a broad-spectrum antibiotic that targets Gram-negative enteric bacteria by inhibiting DNA gyrase and topoisomerase IV, thereby preventing bacterial replication. VSL#3 is a high-potency probiotic containing 450 billion CFU of multiple bacterial strains, including Lactobacilli, Bifidobacteria, and Streptococcus thermophilus. It is intended to modulate the intestinal microbiota, enhance the mucosal barrier, and reduce bacterial translocation from the gut to the ascitic fluid. The regimen is studied as a strategy to prevent SBP while potentially mitigating the risks of antibiotic resistance associated with long-term quinolone prophylaxis.
- Brand names
- VSL#3Noroxin
- Other names
- probiotics + norfloxacinVSL#3 + norfloxacin
02
Targets
Topo IV (Bacterial Topoisomerase IV)DNA gyrase
Beyond the preview
Go deeper on probiotics + norfloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on probiotics + norfloxacin.